A novel monoclonal antibody specific for canine CD25 (P4A10): Selection and evaluation of canine Tregs

被引:27
作者
Abrams, V. Kraig [1 ]
Hwang, Billanna [1 ]
Lesnikova, Marina [1 ]
Gass, M. John [1 ]
Wayner, Elizabeth [1 ]
Castilla-Llorente, Cristina [1 ]
Georges, George E. [1 ,2 ]
Nash, Richard A. [1 ,2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Univ Washington, Sch Med, Seattle, WA USA
关键词
Monoclonal antibody; Cd25; Regulatory T-cells; Dog; REGULATORY T-CELLS; MULTIPLE-SCLEROSIS; ANTI-CD25; ANTIBODY; DACLIZUMAB; EXPRESSION; RECEPTOR; FOXP3; INTERLEUKIN-2-RECEPTOR; TOLERANCE; REJECTION;
D O I
10.1016/j.vetimm.2009.12.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A monoclonal antibody (mAb), P4A10, was made to the canine interleukin-2 receptor alpha chain (IL-2R alpha: p55: Tac antigen: CD25) to facilitate studies of canine regulatory T-cells (Treg). By non-reduced Western blot, P4A10 bound to a 55 kDa protein, the size of human IL-2R alpha. In flow cytometry assays, it reacted with a minor population of circulating dog CD3(+)CD4(+) T-cells and the majority (>60%) of in vitro PMA-Ionomycin (PMA-IO)-activated canine CD3(+) T-cells. P4A10 recognized a hematopoietic cell population enriched for FoxP3+ cells as measured by flow cytometry. The P4A10-selected fractions of T-cells had significantly increased copy numbers of CD25, FoxP3, IL-10, and TGF beta as detected by RT-PCR (reverse transcriptase-PCR) compared to the negative fractions. The P4A10-selected cells inhibited H-3 (tritiated) thymidine incorporation in a mixed leukocyte reaction (MLR) containing responders of the same origin. P4A10-selected T-cells from fresh peripheral blood mononuclear cells had less FoxP3 (p = 0.07) by qRT-PCR (quantitative RT-PCR) and were less suppressive (p = 0.01) than in vitro alloantigen-activated Treg. The mAb P4A10 is specific for canine CD25 and can be used to facilitate studies of CD25+FoxP3+ Treg in this clinically relevant large animal model. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:257 / 265
页数:9
相关论文
共 37 条
[11]   Control of regulatory T cell development by the transcription factor Foxp3 [J].
Hori, S ;
Nomura, T ;
Sakaguchi, S .
SCIENCE, 2003, 299 (5609) :1057-1061
[12]   Phenotypic and functional characterisation of porcine CD4+CD25high regulatory T cells [J].
Kaeser, Tobias ;
Gerner, Wilhelm ;
Hammer, Sabine E. ;
Patzl, Martina ;
Saalmueller, Armin .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2008, 122 (1-2) :153-158
[13]   Cloning of feline FOXP3 and detection of expression in CD4+CD25+ regulatory T cells [J].
Lankford, Susan ;
Petty, Christopher ;
La Voy, Alora ;
Reckling, Stacie ;
Tompkins, Wayne ;
Dean, Gregg A. .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2008, 122 (1-2) :159-166
[14]   A MONOCLONAL-ANTIBODY THAT APPEARS TO RECOGNIZE THE RECEPTOR FOR HUMAN T-CELL GROWTH-FACTOR - PARTIAL CHARACTERIZATION OF THE RECEPTOR [J].
LEONARD, WJ ;
DEPPER, JM ;
UCHIYAMA, T ;
SMITH, KA ;
WALDMANN, TA ;
GREENE, WC .
NATURE, 1982, 300 (5889) :267-269
[15]  
LESNIKOVA M, 2005, BLOOD 1, V106, pA867
[16]   Ex vivo expanded T regulatory (Treg) cells block conversion of mixed chimeras to complete donor chimerism. [J].
Lesnikova, Marina ;
Nikitine, Alla ;
Mason, Nicola ;
Nash, Richard A. ;
Georges, George E. .
BLOOD, 2006, 108 (11) :382B-382B
[17]   The Antibody against Human CD25, ACT-1, Recognizes Canine T-lymphocytes in the G2/M and G0/G1 Phases of the Cell Cycle during Proliferation [J].
Masuda, Kenichi ;
Yasuda, Nobutaka .
JOURNAL OF VETERINARY MEDICAL SCIENCE, 2008, 70 (11) :1285-1287
[18]   Advances in interleukin 2 receptor targeted treatment [J].
Morris, JC ;
Waldmann, TA .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 :109-114
[19]   Immunomodulatory Effects of Mixed Hematopoietic Chimerism: Immune Tolerance in Canine Model of Lung Transplantation [J].
Nash, R. A. ;
Yunosov, M. ;
Abrams, K. ;
Hwang, B. ;
Castilla-Llorente, C. ;
Chen, P. ;
Farivar, A. S. ;
Georges, G. E. ;
Hackman, R. C. ;
Lamm, W. J. E. ;
Lesnikova, M. ;
Ochs, H. D. ;
Randolph-Habecker, J. ;
Ziegler, S. F. ;
Storb, R. ;
Storer, B. ;
Madtes, D. K. ;
Glenny, R. ;
Mulligan, M. S. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) :1037-1047
[20]   Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].
Nashan, B ;
Moore, R ;
Amlot, P ;
Schmidt, AG ;
Abeywickrama, K ;
Soulillou, JP .
LANCET, 1997, 350 (9086) :1193-1198